Home / BMRN : NASDAQ

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does BMRN make money? Does BMRN have pricing power? What's the Earnings Whisper? Will BMRN profit more as the business scales? What is BMRN's management track record? Is BMRN's current price justified?

BioMarin Pharmaceutical Inc.

$65.68 +$6.23 (+10.48%)

NASDAQ · 11 Sep 2026 20:00 UTC

Previous Close

$65.51

Day Range

$65.28$66

Year Range

$49.26$70.98

Market Cap

12.69B

AVG Volume

2.11M

Trailing/Forward PE

172.84/9.86

PEG ratio

5.33

Dividend Yield

Next Earnings Date

2026-10-26

Primary Exchange

NASDAQ

Revenue (USD) · TTM

BMRN Revenue (USD) · TTM by quarter
Period	Revenue (USD) · TTM
26 Q2	3.41B
26 Q1	3.24B
25 Q4	3.22B
25 Q3	3.09B
25 Q2	3.06B
25 Q1	2.95B
24 Q4	2.85B
24 Q3	2.75B
24 Q2	2.59B
24 Q1	2.47B

Net Income (USD) · TTM

BMRN Net Income (USD) · TTM by quarter
Period	Net Income (USD) · TTM
26 Q2	72.97M
26 Q1	268.74M
25 Q4	348.9M
25 Q3	520.42M
25 Q2	657.24M
25 Q1	523.88M
24 Q4	426.86M
24 Q3	322.29M
24 Q2	256.59M
24 Q1	205.46M

Operating Income (USD) · TTM

BMRN Operating Income (USD) · TTM by quarter
Period	Operating Income (USD) · TTM
26 Q2	273.26M
26 Q1	439.21M
25 Q4	533.48M
25 Q3	615.5M
25 Q2	776.08M
25 Q1	619.64M
24 Q4	484.21M
24 Q3	337.03M
24 Q2	253.66M
24 Q1	198.77M

EBITDA (USD) · TTM

BMRN EBITDA (USD) · TTM by quarter
Period	EBITDA (USD) · TTM
26 Q2	385.69M
26 Q1	482.49M
25 Q4	572.94M
25 Q3	772.37M
25 Q2	934.04M
25 Q1	777.11M
24 Q4	650.53M
24 Q3	506.72M
24 Q2	421.44M
24 Q1	359.25M

Cash Flows (USD) · TTM

BMRN Cash Flows (USD) · TTM by quarter
Period	Cash Flows (USD) · TTM
26 Q2	732.88M
26 Q1	761.75M
25 Q4	719.65M
25 Q3	826.06M
25 Q2	691.43M
25 Q1	620.18M
24 Q4	475.42M
24 Q3	300.88M
24 Q2	212.8M
24 Q1	163.21M

EPS (USD) · TTM

BMRN EPS (USD) · TTM by quarter
Period	EPS (USD) · TTM
26 Q2	0.39
26 Q1	1.39
25 Q4	1.8
25 Q3	2.66
25 Q2	3.37
25 Q1	2.69
24 Q4	2.2
24 Q3	1.67
24 Q2	1.33
24 Q1	1.07

Expenses (USD) · TTM

BMRN Expenses (USD) · TTM by quarter
Period	Expenses (USD) · TTM
26 Q2	2.84B
26 Q1	2.62B
25 Q4	2.54B
25 Q3	1.96B
25 Q2	1.71B
25 Q1	1.77B
24 Q4	1.85B
24 Q3	1.91B
24 Q2	1.84B
24 Q1	1.78B

Shares Outstanding (USD) · TTM

BMRN Shares Outstanding (USD) · TTM by quarter
Period	Shares Outstanding (USD) · TTM
26 Q2	-176.55M
26 Q1	-120.21M
25 Q4	-103.85M
25 Q3	-147.64M
25 Q2	-141.86M
25 Q1	-142.24M
24 Q4	-201.57M
24 Q3	-204.51M
24 Q2	-209.41M
24 Q1	-211.65M

Employee Count

BMRN Employee Count by quarter
Period	Employee Count
2025	3.22K
2024	3.04K
2023	3.4K
2022	3.08K
2021	3.04K
2020	3.06K
2019	3K
2018	2.85K
2017	2.58K
2016	2.29K

PE Ratio

BMRN PE Ratio by quarter
Period	PE Ratio
Sep 26	173.68
Sep 26	175.92
Aug 26	171.01
Aug 26	176.37
Aug 26	178.12
Aug 26	168.73
Jul 26	42.99
Jul 26	42.5
Jul 26	42.68
Jul 26	42.35
Jul 26	42.25
Jun 26	42.26
Jun 26	39.17
Jun 26	40.08
Jun 26	40.66
May 26	41.04
May 26	38.74
May 26	37.11
May 26	38.72
May 26	29.72
Apr 26	29.23
Apr 26	30.04
Apr 26	29.97
Apr 26	30.51
Mar 26	29.76
Mar 26	29.75
Mar 26	32.16
Mar 26	33.6
Feb 26	33.93
Feb 26	23.65
Feb 26	22.09
Feb 26	21.45
Jan 26	20.86
Jan 26	20.74
Jan 26	20.14
Jan 26	21.75
Jan 26	21.94
Dec 25	22.12
Dec 25	22.56
Dec 25	19.67
Dec 25	19.7
Nov 25	20.64
Nov 25	20.18
Nov 25	20.2
Nov 25	18.99
Oct 25	19.77
Oct 25	15.87
Oct 25	15.52
Oct 25	15.24
Oct 25	16.15
Sep 25	15.69
Sep 25	15.83
Sep 25	15.76
Sep 25	16.83
Aug 25	16.97
Aug 25	17.06
Aug 25	16.76
Aug 25	16.7
Aug 25	21.19
Jul 25	21.51
Jul 25	20.88
Jul 25	21.18
Jul 25	20.96
Jun 25	20.11
Jun 25	20.05
Jun 25	20.49
Jun 25	20.65
May 25	21.17
May 25	20.98
May 25	21.61
May 25	21.46
May 25	22.61
Apr 25	28.28
Apr 25	26.43
Apr 25	25.38
Apr 25	26.92
Mar 25	31.91
Mar 25	31.82
Mar 25	31.02
Mar 25	32.27
Feb 25	31.79
Feb 25	40.33
Feb 25	38.32
Feb 25	37.77
Jan 25	37.44
Jan 25	36.47
Jan 25	36.36
Jan 25	39.81
Jan 25	39.49
Dec 24	39.52
Dec 24	38.8
Dec 24	39
Dec 24	39.43
Nov 24	39.01
Nov 24	37.97
Nov 24	37.47
Nov 24	39.63
Nov 24	39.35
Oct 24	51.66
Oct 24	51.95

Free Cash Flow Yield

BMRN Free Cash Flow Yield by quarter
Period	Free Cash Flow Yield
Sep 26	5.78%
Sep 26	5.71%
Aug 26	5.87%
Aug 26	5.69%
Aug 26	5.64%
Aug 26	5.95%
Jul 26	6.59%
Jul 26	6.67%
Jul 26	6.64%
Jul 26	6.69%
Jul 26	6.71%
Jun 26	6.71%
Jun 26	7.24%
Jun 26	7.07%
Jun 26	6.97%
May 26	6.91%
May 26	7.32%
May 26	7.64%
May 26	7.32%
May 26	6.94%
Apr 26	7.06%
Apr 26	6.87%
Apr 26	6.88%
Apr 26	6.76%
Mar 26	6.93%
Mar 26	6.93%
Mar 26	6.41%
Mar 26	6.14%
Feb 26	6.08%
Feb 26	6.71%
Feb 26	7.19%
Feb 26	7.4%
Jan 26	7.61%
Jan 26	7.65%
Jan 26	7.88%
Jan 26	7.3%
Jan 26	7.24%
Dec 25	7.18%
Dec 25	7.03%
Dec 25	8.07%
Dec 25	8.06%
Nov 25	7.69%
Nov 25	7.87%
Nov 25	7.86%
Nov 25	8.36%
Oct 25	8.03%
Oct 25	6.63%
Oct 25	6.78%
Oct 25	6.9%
Oct 25	6.52%
Sep 25	6.71%
Sep 25	6.64%
Sep 25	6.68%
Sep 25	6.25%
Aug 25	6.2%
Aug 25	6.17%
Aug 25	6.28%
Aug 25	6.3%
Aug 25	5.59%
Jul 25	5.5%
Jul 25	5.67%
Jul 25	5.59%
Jul 25	5.65%
Jun 25	5.89%
Jun 25	5.9%
Jun 25	5.78%
Jun 25	5.73%
May 25	5.59%
May 25	5.64%
May 25	5.48%
May 25	5.52%
May 25	5.24%
Apr 25	3.94%
Apr 25	4.21%
Apr 25	4.39%
Apr 25	4.14%
Mar 25	3.49%
Mar 25	3.5%
Mar 25	3.59%
Mar 25	3.45%
Feb 25	3.5%
Feb 25	2.32%
Feb 25	2.44%
Feb 25	2.47%
Jan 25	2.49%
Jan 25	2.56%
Jan 25	2.57%
Jan 25	2.34%
Jan 25	2.36%
Dec 24	2.36%
Dec 24	2.41%
Dec 24	2.39%
Dec 24	2.37%
Nov 24	2.39%
Nov 24	2.46%
Nov 24	2.49%
Nov 24	2.36%
Nov 24	2.37%
Oct 24	1.61%
Oct 24	1.6%

Price to Sales

BMRN Price to Sales by quarter
Period	Price to Sales
Sep 26	3.72
Sep 26	3.77
Aug 26	3.66
Aug 26	3.78
Aug 26	3.82
Aug 26	3.61
Jul 26	3.56
Jul 26	3.52
Jul 26	3.54
Jul 26	3.51
Jul 26	3.5
Jun 26	3.5
Jun 26	3.25
Jun 26	3.32
Jun 26	3.37
May 26	3.4
May 26	3.21
May 26	3.08
May 26	3.21
May 26	3.22
Apr 26	3.17
Apr 26	3.25
Apr 26	3.25
Apr 26	3.3
Mar 26	3.22
Mar 26	3.22
Mar 26	3.48
Mar 26	3.64
Feb 26	3.68
Feb 26	3.98
Feb 26	3.72
Feb 26	3.61
Jan 26	3.51
Jan 26	3.49
Jan 26	3.39
Jan 26	3.66
Jan 26	3.69
Dec 25	3.72
Dec 25	3.8
Dec 25	3.31
Dec 25	3.31
Nov 25	3.47
Nov 25	3.39
Nov 25	3.4
Nov 25	3.19
Oct 25	3.32
Oct 25	3.4
Oct 25	3.33
Oct 25	3.27
Oct 25	3.46
Sep 25	3.37
Sep 25	3.4
Sep 25	3.38
Sep 25	3.61
Aug 25	3.64
Aug 25	3.66
Aug 25	3.6
Aug 25	3.58
Aug 25	3.76
Jul 25	3.82
Jul 25	3.71
Jul 25	3.76
Jul 25	3.72
Jun 25	3.57
Jun 25	3.56
Jun 25	3.64
Jun 25	3.67
May 25	3.76
May 25	3.73
May 25	3.84
May 25	3.81
May 25	4.02
Apr 25	4.23
Apr 25	3.95
Apr 25	3.8
Apr 25	4.03
Mar 25	4.77
Mar 25	4.76
Mar 25	4.64
Mar 25	4.83
Feb 25	4.75
Feb 25	4.72
Feb 25	4.49
Feb 25	4.42
Jan 25	4.38
Jan 25	4.27
Jan 25	4.26
Jan 25	4.66
Jan 25	4.62
Dec 24	4.63
Dec 24	4.54
Dec 24	4.57
Dec 24	4.62
Nov 24	4.57
Nov 24	4.45
Nov 24	4.39
Nov 24	4.64
Nov 24	4.61
Oct 24	5.12
Oct 24	5.15

EV/EBITDA

BMRN EV/EBITDA by quarter
Period	EV/EBITDA
Sep 26	41.49
Sep 26	41.91
Aug 26	40.98
Aug 26	42
Aug 26	42.33
Aug 26	40.55
Jul 26	22.32
Jul 26	22.05
Jul 26	22.15
Jul 26	21.96
Jul 26	21.91
Jun 26	21.92
Jun 26	20.2
Jun 26	20.7
Jun 26	21.03
May 26	21.23
May 26	19.96
May 26	19.05
May 26	19.95
May 26	16.49
Apr 26	16.2
Apr 26	16.69
Apr 26	16.65
Apr 26	16.98
Mar 26	16.52
Mar 26	16.52
Mar 26	17.98
Mar 26	18.86
Feb 26	19.06
Feb 26	14.8
Feb 26	13.75
Feb 26	13.32
Jan 26	12.93
Jan 26	12.84
Jan 26	12.44
Jan 26	13.53
Jan 26	13.65
Dec 25	13.77
Dec 25	14.07
Dec 25	12.12
Dec 25	12.15
Nov 25	12.77
Nov 25	12.47
Nov 25	12.48
Nov 25	11.66
Oct 25	12.19
Oct 25	10.28
Oct 25	10.04
Oct 25	9.84
Oct 25	10.47
Sep 25	10.15
Sep 25	10.25
Sep 25	10.2
Sep 25	10.95
Aug 25	11.06
Aug 25	11.12
Aug 25	10.91
Aug 25	10.86
Aug 25	13.42
Jul 25	13.64
Jul 25	13.22
Jul 25	13.41
Jul 25	13.27
Jun 25	12.69
Jun 25	12.65
Jun 25	12.95
Jun 25	13.06
May 25	13.41
May 25	13.28
May 25	13.7
May 25	13.6
May 25	14.38
Apr 25	17.73
Apr 25	16.52
Apr 25	15.83
Apr 25	16.84
Mar 25	20.12
Mar 25	20.06
Mar 25	19.53
Mar 25	20.35
Feb 25	20.04
Feb 25	25
Feb 25	23.72
Feb 25	23.38
Jan 25	23.16
Jan 25	22.55
Jan 25	22.48
Jan 25	24.67
Jan 25	24.47
Dec 24	24.49
Dec 24	24.03
Dec 24	24.16
Dec 24	24.43
Nov 24	24.17
Nov 24	23.5
Nov 24	23.19
Nov 24	24.56
Nov 24	24.38
Oct 24	31.16
Oct 24	31.33

Price/Operating Cashflow

BMRN Price/Operating Cashflow by quarter
Period	Price/Operating Cashflow
Sep 26	14.79
Sep 26	14.98
Aug 26	14.56
Aug 26	15.02
Aug 26	15.16
Aug 26	14.37
Jul 26	13.22
Jul 26	13.06
Jul 26	13.12
Jul 26	13.02
Jul 26	12.99
Jun 26	12.99
Jun 26	12.04
Jun 26	12.32
Jun 26	12.5
May 26	12.61
May 26	11.91
May 26	11.41
May 26	11.9
May 26	12.52
Apr 26	12.32
Apr 26	12.66
Apr 26	12.63
Apr 26	12.86
Mar 26	12.54
Mar 26	12.54
Mar 26	13.55
Mar 26	14.16
Feb 26	14.3
Feb 26	13.46
Feb 26	12.58
Feb 26	12.21
Jan 26	11.88
Jan 26	11.81
Jan 26	11.47
Jan 26	12.39
Jan 26	12.49
Dec 25	12.6
Dec 25	12.85
Dec 25	11.2
Dec 25	11.22
Nov 25	11.75
Nov 25	11.49
Nov 25	11.5
Nov 25	10.81
Oct 25	11.26
Oct 25	13.6
Oct 25	13.3
Oct 25	13.06
Oct 25	13.84
Sep 25	13.44
Sep 25	13.57
Sep 25	13.5
Sep 25	14.42
Aug 25	14.55
Aug 25	14.63
Aug 25	14.37
Aug 25	14.31
Aug 25	15.86
Jul 25	16.09
Jul 25	15.62
Jul 25	15.84
Jul 25	15.68
Jun 25	15.05
Jun 25	15
Jun 25	15.33
Jun 25	15.45
May 25	15.84
May 25	15.69
May 25	16.16
May 25	16.05
May 25	16.92
Apr 25	21.07
Apr 25	19.7
Apr 25	18.91
Apr 25	20.06
Mar 25	23.78
Mar 25	23.71
Mar 25	23.12
Mar 25	24.04
Feb 25	23.69
Feb 25	31.34
Feb 25	29.78
Feb 25	29.36
Jan 25	29.09
Jan 25	28.35
Jan 25	28.25
Jan 25	30.94
Jan 25	30.69
Dec 24	30.72
Dec 24	30.15
Dec 24	30.31
Dec 24	30.65
Nov 24	30.32
Nov 24	29.51
Nov 24	29.12
Nov 24	30.8
Nov 24	30.58
Oct 24	40.31
Oct 24	40.53

Price to Book

BMRN Price to Book by quarter
Period	Price to Book
Sep 26	2
Sep 26	2.03
Aug 26	1.97
Aug 26	2.04
Aug 26	2.06
Aug 26	1.95
Jul 26	1.86
Jul 26	1.84
Jul 26	1.85
Jul 26	1.83
Jul 26	1.83
Jun 26	1.83
Jun 26	1.69
Jun 26	1.73
Jun 26	1.76
May 26	1.78
May 26	1.68
May 26	1.61
May 26	1.68
May 26	1.7
Apr 26	1.68
Apr 26	1.72
Apr 26	1.72
Apr 26	1.75
Mar 26	1.71
Mar 26	1.71
Mar 26	1.84
Mar 26	1.93
Feb 26	1.94
Feb 26	2.03
Feb 26	1.9
Feb 26	1.84
Jan 26	1.79
Jan 26	1.78
Jan 26	1.73
Jan 26	1.87
Jan 26	1.88
Dec 25	1.9
Dec 25	1.94
Dec 25	1.69
Dec 25	1.69
Nov 25	1.77
Nov 25	1.73
Nov 25	1.74
Nov 25	1.63
Oct 25	1.7
Oct 25	1.73
Oct 25	1.69
Oct 25	1.66
Oct 25	1.76
Sep 25	1.71
Sep 25	1.73
Sep 25	1.72
Sep 25	1.83
Aug 25	1.85
Aug 25	1.86
Aug 25	1.83
Aug 25	1.82
Aug 25	1.92
Jul 25	1.95
Jul 25	1.89
Jul 25	1.92
Jul 25	1.9
Jun 25	1.82
Jun 25	1.81
Jun 25	1.85
Jun 25	1.87
May 25	1.91
May 25	1.9
May 25	1.95
May 25	1.94
May 25	2.04
Apr 25	2.13
Apr 25	1.99
Apr 25	1.91
Apr 25	2.03
Mar 25	2.41
Mar 25	2.4
Mar 25	2.34
Mar 25	2.43
Feb 25	2.4
Feb 25	2.4
Feb 25	2.28
Feb 25	2.25
Jan 25	2.23
Jan 25	2.17
Jan 25	2.16
Jan 25	2.37
Jan 25	2.35
Dec 24	2.35
Dec 24	2.31
Dec 24	2.32
Dec 24	2.35
Nov 24	2.32
Nov 24	2.26
Nov 24	2.23
Nov 24	2.36
Nov 24	2.34
Oct 24	2.51
Oct 24	2.52

No video analysis for this stock yet. Request one from our team.

News: BMRN

defenseworld.net · 12 Sep 2026

BioMarin Pharmaceutical Inc. $BMRN Shares Acquired by Amundi

Amundi lifted its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) by 37.8% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 259,782 shares of the biotechnology company's stock after acquiring an additional 71,246 shares during the period. Amundi

seekingalpha.com · 10 Sep 2026

BioMarin Pharmaceutical Inc. (BMRN) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

seekingalpha.com · 10 Sep 2026

BioMarin Pharmaceutical Inc. (BMRN) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

seekingalpha.com · 9 Sep 2026

BioMarin Pharmaceutical Inc. (BMRN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

prnewswire.com · 9 Sep 2026

BioMarin Announces Positive Results of Phase 3 VOXZOGO® (vosoritide) Study in Hypochondroplasia Published in NEJM Evidence

Detailed Phase 3 CANOPY-HCH-3 data in children living with hypochondroplasia also featured in a late-breaking oral presentation at the European Society for Paediatric Endocrinology (ESPE) 2026 Annual Meeting VOXZOGO demonstrated statistically significant improvements across multiple measures of growth, including annualized growth velocity, standing height, height Z-score and arm span BioMarin recently submitted a supplemental New Drug Application (sNDA) to the FDA to support expanding treatment with VOXZOGO to include children with hypochondroplasia SAN RAFAEL, Calif., Sept. 9, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data from the Phase 3 CANOPY-HCH-3 study evaluating VOXZOGO® (vosoritide) in children with hypochondroplasia were published in New England Journal of Medicine (NEJM) Evidence and presented at the European Society for Paediatric Endocrinology (ESPE) 2026 Annual Meeting.

zacks.com · 3 Sep 2026

How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset

BMRN turns a competitive threat into a royalty stream as Ascendis pays royalties on Yuviwel sales, reshaping the economics of competition.

prnewswire.com · 2 Sep 2026

BioMarin to Participate in Upcoming Investor Conferences

Wells Fargo 21st Annual Healthcare Conference, September 9 at 3:00 pm EST Cantor Global Healthcare Conference 2026, September 10 at 10:20 am EST Citi's 2026 Biopharma Back to School Conference, September 10 at 1:00 pm EST Morgan Stanley 24th Annual Global Healthcare Conference, September 14 at 10:00 am EST SAN RAFAEL, Calif., Sept. 2, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at upcoming investor conferences in September.

zacks.com · 1 Sep 2026

4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects

ALNY, BMRN, RARE and BBIO offer rare-disease growth potential through strong products, pipeline catalysts and high unmet medical needs.